Source: https://patents.google.com/patent/US20060088593A1/en
Timestamp: 2019-08-21 18:40:45
Document Index: 46695969

Matched Legal Cases: ['art 520', 'art 520', 'art 520', 'art 520', 'art 520', 'Application No. 20040175463']

US20060088593A1 - Dosage forms having a microreliefed surface and methods and apparatus for their production - Google Patents
US20060088593A1
US20060088593A1 US11/236,022 US23602205A US2006088593A1 US 20060088593 A1 US20060088593 A1 US 20060088593A1 US 23602205 A US23602205 A US 23602205A US 2006088593 A1 US2006088593 A1 US 2006088593A1
US11/236,022
2004-10-27 Priority to US62314104P priority Critical
2005-09-27 Application filed by Johnson and Johnson Consumer Inc filed Critical Johnson and Johnson Consumer Inc
2005-09-27 Priority to US11/236,022 priority patent/US20060088593A1/en
2005-12-07 Assigned to MCNEIL-PPC, INC. reassignment MCNEIL-PPC, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BUNICK, FRANK J., CHEN, JEN-CHI
2006-04-27 Publication of US20060088593A1 publication Critical patent/US20060088593A1/en
This Application claims the benefit of U.S. application Ser. No. 60/623,141 filed on 27 Oct. 2004, which is incorporated by reference in its entirety herein.
One currently used technique for providing unique dosage form identification includes the use of intagliations. Intagliations are impressed marks typically-achieved by engraving or impressing a graphical representation, for example a figure, mark, character, symbol such as a letter, a name, a logo, a pictoral representation, and the like, or any combination thereof, in a tablet or other solid dosage form, such as by a punching procedure. U.S. Pat. No. 5,827,535, for example, describes soft gelatin capsules with an external surface having defined thereon an impressed graphical representation. U.S. Pat. No. 5,405,642 discloses a method of highlighting intagliations in white or colored coated tablets by spraying onto said tablets a suspension comprising a filling material having a different color, a waxy material and a solvent, then removing the solvent and the excess filling and waxy material. However, it is often difficult to maintain the waxy material in an amount sufficient to promote suitable bonding of the filling material, yet be suitably removable with solvent.
In another embodiment, the second molded portion is substantially free of pores having a diameter of about 0.5 microns to about 5.0 microns.
FIG. 9A depicts a cross-sectional view of another dosage form of this invention containing a core, a top coating, and a microreliefed-waxy layer therebeween, and FIG. 9B depicts a cross-sectional view of the same dosage form after exposure to heat.
As used herein, the term “dosage form” applies to any ingestible forms, including confections. In one embodiment, dosage forms are solid, semi-solid, or liquid compositions designed to contain a specific pre-determined amount (i.e. dose) of a certain ingredient, for example an active ingredient as defined below. Suitable dosage forms may be pharmaceutical drug delivery systems, including those for oral administration, buccal administration, rectal administration, topical, transdermal, or mucosal delivery, or subcutaneous implants, or other implanted drug delivery systems; or compositions for delivering minerals, vitamins and other nutraceuticals, oral care agents, flavorants, and the like. In one embodiment, the dosage forms of the present invention are considered to be solid; however, they may contain liquid or semi-solid components. In another embodiment, the dosage form is an orally administered system for delivering a pharmaceutical active ingredient to the gastrointestinal tract of a human. In yet another embodiment, the dosage form is an orally administered “placebo” system containing pharmaceutically inactive ingredients, and the dosage form is designed to have the same appearance as a particular pharmaceutically active dosage form, such as may be used for control purposes in clinical studies to test, for example, the safety and efficacy of a particular pharmaceutically active ingredient.
The core-may be in a variety of different shapes. For example, in one embodiment the core may be in the shape of a truncated cone. In other embodiments the core may be shaped as a polyhedron, such as a cube, pyramid, prism, or the like; or may have the geometry of a space figure with some non-flat faces, such as a cone, cylinder, sphere, torus, or the like. Exemplary core shapes which may be employed include tablet shapes formed from compression tooling shapes described by “The Elizabeth Companies Tablet Design Training Manual” (Elizabeth Carbide Die Co., Inc., p. 7 (McKeesport, Pa.) (incorporated herein by reference) as follows (the tablet shape corresponds inversely to the shape of the compression tooling):
In another embodiment, the core may be prepared by the compression methods and apparatus described in U.S. Patent Application Publication No. 20040156902. Specifically, the core may be made using a rotary compression module comprising a fill zone, insertion zone, compression zone, ejection zone, and purge zone in a single apparatus having a double row die construction as shown in FIG. 6 of U.S. Patent Application Publication No. 20040156902. The dies of the compression module may then be filled using the assistance of a vacuum, with filters located in or near each die. The purge zone of the compression module includes an optional powder recovery system to recover excess powder from the filters and return the powder to the dies.
In one embodiment, the first portion or core may also be prepared by thermal setting injection molding using the method and apparatus in which the mold is maintained at approximately a constant temperature as described in U.S. Patent Application Publication No. 20030124183. In this embodiment, the first portion or core may be formed by injecting a starting material in flowable form into a molding chamber. The starting material may comprise an active ingredient and a thermally responsive material, which is introduced to the mold at a temperature above the glass transition temperature or set temperature of the thermally responsive material but below the decomposition temperature of the active ingredient. The starting material is then cooled and solidified in the molding chamber into a desired shaped form (i.e. the shape of the mold). The starting material, when at a temperature that is greater than its glass transition temperature or its set temperature, is sufficiently flowable to be easily injected or pumped into the molding chamber.
Any thickener known in the art may optionally be added to the thermally responsive material. Additional suitable thickeners include, but are not limited to, cyclodextrin, crystallizable carbohydrates, and the like, and derivatives and combinations thereof. Suitable crystallizable carbohydrates include the monosaccharides and the oligosaccharides. Of the monosaccharides, the aldohexoses e.g., the D and L isomers of allose, altrose, glucose, mannose, gulose, idbse, galactose, talose, and the ketohexoses e.g., the D and L isomers of fructose and sorbose along with their hydrogenated analogs: e.g., glucitol (sorbitol), and mannitol are preferred. Of the oligosaccharides, the 1,2-disaccharides sucrose and trehalose, the 1,4-disaccharides maltose, lactose, and cellobiose, and the 1,6-disaccharides gentiobiose and melibiose, as well as the trisaccharide raffinose are preferred along with the isomerized form of sucrose known as isomaltulose and its hydrogenated analog isomalt. Other hydrogenated forms of reducing disaccharides (such as maltose and lactose), for example, maltitol and lactitol are also preferred. Additionally, the hydrogenated forms of the aldopentoses: e.g., D and L ribose, arabinose, xylose, and lyxose and the hydrogenated forms of the aldotetroses: e.g., D and L erythrose and threose are suitable and are exemplified by xylitol and erythritol, respectively.
In another embodiment, the core may be a hollow or evacuated core. For example, the core may be an empty capsule shell. Alternatively, a hollow core may be prepared for example by injection molding or shell molding. In one such method, flowable material is injected into a mold cavity, the cavity is brought to a temperature at which the outer surface of the core (which is in contact with the mold) begins to solidify or set. The excess flowable material from the center of the core is then withdrawn from the mold using suitable means, for example a piston pump. In another such method, an empty capsule is used as a sub-core, and a coating layer is formed thereon by methods known in the art such as, for example, spray-coating, dip-coating, injection cycle molding as described in, for example, U.S. Patent Application Publication No. 20030086973. In certain embodiments of the invention, the core may further comprise any of the aforementioned subcoatings applied by any method known in the art, for example spraying, compression, or molding. In certain other embodiments of the invention, the core may be substantially free of a subcoating.
In one embodiment of the invention, only the core comprises one or more active ingredients. In another embodiment of this invention, only the inlaid portion comprises one or more active ingredients. In yet another embodiment of-this invention, only the insert comprises one or more active ingredients. In yet another embodiment of this invention, both the core and inlaid portion comprise one or more active ingredients. In yet another embodiment of this invention, one or more of the core, the inlaid portion, or the insert comprises one or more of the active ingredients. Optionally, any of the coatings may further comprise one or more active ingredients.
In an alternative embodiment shown in FIGS. 6A and 6D, a removable change-part 520,520′ such as a thin film or foil, containing the desired microrelief 512 may be inserted on to the internal surface 506′ of the upper mold, or in the internal surface of one of the dies used in a tablet press, via any known means for removably attaching the change-part such as, for example adhesives. In alternative embodiment shown in FIG. 6B and FIG. 6C, respectively, the removable change-part 520 may extend across the entire internal surface 506′ of the upper mold 506 (see changepart 520″ in FIG. 6B), or may be friction-fit into an opening in the upper mold 506 (see changepart 520″′ in FIG. 6C). Advantageously, the changepart 520 used in this embodiment could easily be removed and replaced with another changepart having an alternative microrelief pattern with minimal cost and production cycle time loss.
Suitable changepart materials include any substance that is capable of holding a microrelief image, such as aluminum, tin, gold, silver, nickel, copper, and their alloys, plastics that are solid at temperature greater than 250° C., and mixtures thereof. The size and thickness of the changepart may vary depending upon, for example, the surface area of dosage form and the desired microrelief pattern, but will generally have a thickness of from about 10 microns to about 5000 microns and a surface area of from about greater than 0% to less than about 100% of the dosage form face, e.g., greater than about 10% and less than about 90% or greater than about 25% and less than about 50%. “Face,” as used herein, is the portion of a compressed tablet formed by the upper and lower punch faces, and includes one-half of the overlap area of a rim as illustrated in U.S. Patent Application Publication No. 20040109889.
Fine evacuation until: 200μ Hg
Another method for producing a dosage form containing unique visual properties includes the application of lines, or fine dots arranged in a line, in a desired pattern onto the surface of a core, which optionally, may be a pattern 610 on the interior surface 602′ of a core cavity 602 as shown in FIG. 3, followed by the application of a coating containing a macrorelief pattern thereon.
The strips may be comprised of any ink or pigment, and optionally may contain an effect pigment. Examples of suitable inks and pigments are those disclosed in, for example, U.S. Pat. Nos. 5,435,840; 5,006,362; and 6,468,561; U.S. Patent Application No. 20040175463; and WO 2004073582.
An alternative method for producing a dosage form containing unique visual properties includes applying to a dosage form either a film that possesses at least one microreliefed surface or a film containing the aforementioned microreliefed flakes. In one embodiment, cores, which may optionally contain at least one cavity and which may further optionally be comprised of sugar in the form of an amorphous glass, may be enrobed with either of these films via the vacuum forming apparatus and processing conditions disclosed in U.S. Patent Application No. US 2003/215585A1. The amount of vacuum applied to the film during processing may depend upon, for example, the thickness of the film, the temperature of the film, the depth of the cavity in the dosage form, and the desired amount of air gap in the dosage form, but typically may range from about 0.005 Torr to about 700 Torr. In embodiments using a film having at least one microreliefed surface, the film can touch the cavity-free core surface so long as the microreliefed surface is proximate to the core to form a plurality of airgaps.
FIG. 3 illustrates one embodiment of the resulting dosage form 604 of the present invention, wherein the core 601 is enrobed with a film 603 having a microreliefed surface 620 and an air gap generated between the inner surface of the film 605 and the bottom interior surface 602′ of the cavity 602. In an alternative embodiment (not shown), the inner surface 605 or both the inner surface 605 and the exterior surface 606 of the film 603 may possess a microreliefed portion over at least a portion of the cavity 602. As a result, incident light 623 is partially reflected as reflected light 625 at the interface between the bottom surface 605 of the film and the air within the cavity 602, and the microreliefed surface 620 appears brighter than that of similar dosage forms enrobed with microreliefed films but lacking an air gap.
Further, the dosage forms may also advantageously provide unique visual and color effects and images to dosage forms, as well as to other toiletry, cosmetic, healthcare, and foodstuffs, such that they possess a unique appearance without the use of inedible metal, dye, color, and ink pigments. In one embodiment, the brightness of the logo or diffractive color pattern of the microrelief on a dosage form may further be enhanced by using a core having a shiny light colored, e.g. white, reflective surface. As used herein, “shiny” or “highly glossy” means that the core, substrate, or dosage form possesses a surface gloss of at least 200, for example between about 200 to about 300. “Surface gloss,” as used herein, refers to the amount of light reflectance as measured at a 60 degree incident angle using the method set forth in Example 7 of U.S. Pat. Application Publication No. 20030072731. For example, in embodiments wherein a highly glossy effect is desired, the core may be comprised of a polyol such as sorbitol, xylitol, mannitol, and the like, or may be coated with a subcoating comprised of, for example, pullulan and other subcoatings as disclosed in U.S. Pat. Nos. 6,248,391; 6,274,162; 5,468,561; 6,448,323; 6,183,808; and 5,662,732; and WO 2004 073582.
Paracetamol DC273N (P.G.S.)- US* 529.1
Paracetamol DC273N (P.G.S.)- US* 400.0
Example 4 Coated Tablets bearing a Microrelief and an Air Gap between the Coatina Laver and the Tablet Surface
Example 6a Color Shifting Tablet by Edible Lenticular Coating
Paracetamol DC273N (P.G.S.)- US 529.1
Example 6b Flip Image Tablet Logo and Dose using Edible Lenticular Coating
a) at least one active ingredient;
b) a first portion comprising a first exterior surface and one or more cavities defining at least one interior surface; and
c) a second molded portion inlaid into the cavities of the first portion and having a second exterior surface,
wherein the first and second portions are in contact at an interface, the second portion comprises a solidified thermally responsive material, and the second exterior surface bears a microrelief.
7. The dosage form of claim 1 wherein the second exterior surface is flush with the first exterior surface.
8. The dosage form of claim 1 wherein the second exterior surface is raised with respect to the first exterior surface.
9. The dosage form of claim 1 wherein the first exterior surface is raised with respect to the second exterior surface.
10. The dosage form of claim 1 wherein the first portion consists essentially of a single homogeneous layer.
11. The dosage form of claim 1, in which the second molded portion comprises at least one active ingredient.
12. The dosage form of claim 1, in which the first portion has a first color and the inlaid second portion has a second color.
13. The dosage form of claim 1, in which the first portion comprises a first active ingredient and the inlaid second portion comprises a second active ingredient which may be the same or different than the first active ingredient.
14. The dosage form of claim 1, in which the first and second portions together provide a prearranged pattern.
15. The dosage form of claim 1, in which the second portion comprises a flavoring agent or sensate.
16. The dosage form of claim 1, in which the interior surface of one or more cavities in the first portion has a draft angle having a value less than zero.
17. The dosage form of claim 1, the interface is substantially coextensive with the interior surface.
18. The dosage form of claim 1, in which the first portion is discontinuous and the second portion is continuous.
19. The dosage form of claim 1, wherein at least one interior surface of said cavities has indentations, and the second molded portion resides substantially conformally upon the indentations.
20. A dosage form comprising:
b) a core having an outer surface; and
c) a shell residing on at least a portion of the core outer surface, said shell comprising a first shell portion having a first shell exterior surface and a second molded shell portion having a second shell exterior surface, said exterior surface bearing a second shell microrelief,
wherein said second molded shell portion is inlaid into the first shell portion and said first and second shell portions are in contact at an interface.
21. The dosage form of claim 20, in which the shell has an outer surface and the second molded shell portion extends from the outer surface of the core to the outer surface of the shell.
22. The dosage form of claim 20, in which the first and second shell portions are discontinuous.
23. The dosage form of claim 19, in which the first shell portion has a first color and the second shell portion has a second color.
24. The dosage form of claim 20, in which the core comprises a compressed powder.
25. The dosage form of claim 20, in which the core comprises an insert.
26. The dosage form of claim 20, in which at least one of the first shell portion or the second shell portion comprises a flavoring agent or a sensate.
27. The dosage form of claim 25, in which at least one of the core, the first shell portion, the second shell portion or the insert comprises an active ingredient.
28. The dosage form of claim 20, in which the first shell portion has an exterior surface bearing a first shell microrelief.
29. The dosage form of claim 28, in which the first shell microrelief is different than the second shell microrelief.
30. The dosage form of claim 20, in which the first shell portion has a first outer surface and the second shell portion has a second outer surface, and the first outer surface and/or the second outer surface is textured.
31. The dosage form of claim 20, in which the shell has an outer surface having a prearranged pattern.
32. The dosage form of claim 20, in which the shell comprises one or more openings therein.
33. The dosage form of claim 20, in which the outer surface of the shell is substantially smooth.
34. The dosage form of claim 20, in which the shell has an outer surface having indentations, letters, symbols or a pattern.
35. The dosage form of claim 20, in which the first shell portion contains indentations, letters, symbols or a pattern.
36. The dosage form of claim 20, in which the second shell portion contains indentations, letters, symbols or a pattern.
37. The dosage form of claim 20, in which the second molded shell portion is substantially free of pores having a diameter of about 0.5 microns to about 5.0 microns.
38. The dosage form of claim 20, in which the first shell portion has a draft angle having a value less than zero at the interface.
39. The dosage form of claim 20, wherein the first and second shell portions comprise a solidified thermally responsive material.
40. The dosage form of claim 20, wherein the exterior surfaces of the first and second shell portions are substantially coplanar.
41. The dosage form of claim 1, wherein the cavities define a plurality of side walls for receiving the inlaid second molded portion, and the side walls have a draft angle less than zero.
42. The dosage form of claim 1, wherein the area of at least one cross-section of the second molded portion is greater than the cross-sectional area of the cavity at the exterior surface of the first portion.
43. A dosage form comprising:
a) at least one active ingredient,
b) a core, and
c) a shell having a first molded shell portion which is discontinuous, and a second molded shell portion which is continuous, said second molded shell portion having an exterior surface bearing a microrelief,
wherein the discontinuities of the first shell portion are filled with the second molded shell portion, and the first and second shell portions are compositionally different.
44. A dosage form comprising:
b) a first portion which comprises an exterior surface and at least one cavity passing through the first portion and defining at least one interior surface; and
c) a second molded portion which is inlaid into the at least one cavity of the first portion and has a first exterior surface and a second exterior surface,
wherein the first and second portions are in contact at an interface, the second portion comprises a solidified thermally responsive material, and the first exterior surface and/or the second exterior surface of the second portion bears a microrelief.
US11/236,022 2004-10-27 2005-09-27 Dosage forms having a microreliefed surface and methods and apparatus for their production Abandoned US20060088593A1 (en)
US62314104P true 2004-10-27 2004-10-27
US11/236,022 US20060088593A1 (en) 2004-10-27 2005-09-27 Dosage forms having a microreliefed surface and methods and apparatus for their production
DE200560019606 DE602005019606D1 (en) 2004-10-27 2005-10-27 Dosage forms with micro-relief surface and method and apparatus for the preparation thereof
BRPI0517377 BRPI0517377A (en) 2004-10-27 2005-10-27 dotatas dosage forms of a surface microrelief and methods and apparatus for producing such
JP2007539177A JP2008518033A (en) 2004-10-27 2005-10-27 METHOD AND APPARATUS FOR microrelief surface with the dosage forms and of making such dosage forms
CA 2587199 CA2587199A1 (en) 2004-10-27 2005-10-27 Dosage forms having a microreliefed surface and methods and apparatus for their production
EP20050823248 EP1811970B1 (en) 2004-10-27 2005-10-27 Dosage forms having a microreliefed surface and methods and apparatus for their production
ARP050104514A AR051941A1 (en) 2004-10-27 2005-10-27 Dosage forms having a surface with microreliefs and methods and apparatus for producion
PCT/US2005/038969 WO2006047738A2 (en) 2004-10-27 2005-10-27 Dosage forms having a microreliefed surface and methods and apparatus for their production
US20060088593A1 true US20060088593A1 (en) 2006-04-27
ID=35695552
US11/236,022 Abandoned US20060088593A1 (en) 2004-10-27 2005-09-27 Dosage forms having a microreliefed surface and methods and apparatus for their production
US (1) US20060088593A1 (en)
EP (1) EP1811970B1 (en)
JP (1) JP2008518033A (en)
AR (1) AR051941A1 (en)
BR (1) BRPI0517377A (en)
CA (1) CA2587199A1 (en)
DE (1) DE602005019606D1 (en)
WO (1) WO2006047738A2 (en)
US20120045499A1 (en) * 2008-12-31 2012-02-23 Cadbury Adams Mexico, S. De R.L. De C.V. Pearlescent pigment surface treatment for confectionery
US4128658A (en) * 1976-08-04 1978-12-05 Allen & Hanburys Limited Aminoalkyl furan derivatives
US5000388A (en) * 1989-07-27 1991-03-19 D.E.M. Controls Of Canada Spray manifolds
US5468561A (en) * 1993-11-05 1995-11-21 Texas Instruments Incorporated Etching and patterning an amorphous copolymer made from tetrafluoroethylene and 2,2-bis(trifluoromethyl)-4,5-difluoro-1,3-dioxole (TFE AF)
US5489936A (en) * 1992-11-03 1996-02-06 Xerox Corporation Fast scan spot correction in a polygon ROS using PWM
US5543370A (en) * 1993-06-11 1996-08-06 Elektroschmelzwerk Kempten Gmbh Composite materials based on boron carbide, titanium diboride and elemental carbon and processes for the preparation of same
US5658589A (en) * 1989-04-28 1997-08-19 Mcneil-Ppc, Inc. Subcoated simulated capsule-like medicament
US5662732A (en) * 1996-08-09 1997-09-02 Bpsi Holdings, Inc. Polish composition
US6063404A (en) * 1997-07-30 2000-05-16 Jenapharm Gmbh & Co. Kg Bioadhesive tablet
US6274162B1 (en) * 2000-01-14 2001-08-14 Bpsi Holdings, Inc. Elegant film coating system
US20010050755A1 (en) * 2000-06-09 2001-12-13 Constantin Bogomolnyi Audio-video recording of overhead projector based presentations
US6349639B1 (en) * 2000-08-22 2002-02-26 Hallmark Cards, Incorporated Paper embossing system with a flexible counter and method of embossing
US6468561B1 (en) * 1986-06-19 2002-10-22 Bpsi Holdings, Inc. Aqueous film coating with improved properties
US20030020179A1 (en) * 2001-07-25 2003-01-30 D'amato Gerald J. Methods and apparatus for aligning an integrated circuit package with an interface
US20030215585A1 (en) * 2002-05-15 2003-11-20 Mcneil-Ppc, Inc. Enrobed core
US20040105692A1 (en) * 2001-07-23 2004-06-03 Takahiro Tamiya Bias applying method for an image forming apparatus and device for the same
US589A (en) 1838-02-03 Joseph smart
US5658A (en) 1848-07-05 Improvement in the manufacture of bromine
CN1750815B (en) 2003-02-20 2010-05-12 Bpsi控股公司 Pearlescent film coating systems and substrates coated therewith
2005-09-27 US US11/236,022 patent/US20060088593A1/en not_active Abandoned
2005-10-27 DE DE200560019606 patent/DE602005019606D1/en active Active
2005-10-27 AR ARP050104514A patent/AR051941A1/en not_active Application Discontinuation
2005-10-27 BR BRPI0517377 patent/BRPI0517377A/en not_active IP Right Cessation
2005-10-27 JP JP2007539177A patent/JP2008518033A/en active Pending
2005-10-27 CA CA 2587199 patent/CA2587199A1/en not_active Abandoned
2005-10-27 WO PCT/US2005/038969 patent/WO2006047738A2/en active Application Filing
2005-10-27 EP EP20050823248 patent/EP1811970B1/en not_active Expired - Fee Related
US6490975B1 (en) * 1999-09-30 2002-12-10 Presstek, Inc. Infrared laser-imageable lithographic printing members and methods of preparing and imaging such printing members
AU2008268554B2 (en) * 2007-06-22 2014-09-04 Mcneil-Ppc, Inc. Laser marked dosage forms
AR051941A1 (en) 2007-02-21
CA2587199A1 (en) 2006-05-04
BRPI0517377A (en) 2008-10-07
WO2006047738A3 (en) 2006-11-09
EP1811970A2 (en) 2007-08-01
EP1811970B1 (en) 2010-02-24
DE602005019606D1 (en) 2010-04-08
JP2008518033A (en) 2008-05-29
WO2006047738A2 (en) 2006-05-04
CA2258159C (en) 2006-03-21 Intraorally rapidly disintegrable tablet
EP1429711B1 (en) 2008-12-31 Method for making an insert
US8673190B2 (en) 2014-03-18 Method for manufacturing dosage forms
US5853762A (en) 1998-12-29 Delivery of controlled-release system(s)
CN100574749C (en) 2009-12-30 Enrobed core
US7361006B2 (en) 2008-04-22 Systems, methods and apparatuses for manufacturing dosage forms
CA2451842C (en) 2008-09-09 Chewable product including active ingredient
JP2011079864A (en) 2011-04-21 Quick dissolve compositions and tablets based thereon
EP2034972B1 (en) 2012-02-22 Enteric coated particles containing an active ingredient
AU7275700A (en) 2001-03-13 Rapidly dissolving dosage form and process for making same
ES2444549T3 (en) 2014-02-25 Dosage form containing a confectionery composition
WO1999065473A1 (en) 1999-12-23 Process for forming chewable quickly dispersing multi-vitamin preparation and product therefrom
CN1249176A (en) 2000-04-05 Soft chew tablet
PT1459740E (en) 2007-07-20 Compositions containing sucralose
US20130281546A1 (en) 2013-10-24 Intrabuccally rapidly disintegrating tablet and a production method of the tablets
EP1614413A2 (en) 2006-01-11 Solid dosage form for acid-labile active ingredient
DE60212475T2 (en) 2007-07-05 The pharmaceutical tablet and a process for their preparation
US20100021507A1 (en) 2010-01-28 Method and Composition for Making an Orally Disintegrating Dosage Form
EP2180886B1 (en) 2016-09-21 Modified release solid or semi-solid dosage forms
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BUNICK, FRANK J.;CHEN, JEN-CHI;REEL/FRAME:017099/0632